When will melanoma vaccines be proven effective?

Journal of Clinical Oncology

Volumn 22, Issue 3, 2004, Pages 387-389

  Sosman, Jeffrey A ^a   Weeraratna, Ashani T ^b   Sondak, Vernon K ^c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE;

HUMAN; MELANOMA; NOTE; PATHOLOGY; SKIN TUMOR; TUMOR RECURRENCE;

CANCER VACCINES; HUMANS; MELANOMA; NEOPLASM RECURRENCE, LOCAL; SKIN NEOPLASMS;

EID: 1442339466     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2004.11.950     Document Type: Review

References (23)

1. Livingston P: The unfulfilled promise of melanoma vaccines. Clin Cancer Res 7: 1837-1838, 2001
2. Rosenberg SA: A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10: 281-287, 1999
3. King M, Spooner D, Rowlands DC: Spontaneous regression of metastatic malignant melanoma of the parotid gland and neck lymph nodes: A case report and a review of the literature. Clin Oncol 13: 466-469, 2001
4. Tuthill RJ, Unger JM, Liu PY, et al: Risk assessment in localized primary cutaneous melanoma: A Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol 118: 504-511, 2002
5. Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17: 2105-2116, 1999
6. Kawakami Y, Eliyahu S, Delgado CH, et al: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T-cells infiltrating into tumor. Proc Natl Acad Sci U S A 91: 3515-3519, 1994
7. Brown CK, Kirkwood JH: Medical management of melanoma. Surg Clin North Am 83: 283-322, 2003
8. Chambers CA, Allison JP: Costimulatory regulation of T cell function. Curr Opin Cell Biol 11: 203-210, 1999
9. Ribas A, Butterfield LH, Glaspy JA, et al: Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 21: 2415-2432, 2003
10. Koutsky LA, Ault KA, Wheeler CM, et al: Proof of principle study investigators: A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347: 1645-1651, 2002
11. Chang MH, Chen CJ, Lai MS, et al: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children: Taiwan Childhood Hepatoma Study Group. N Engl J Med 336: 1855-1859, 1997
12. Kuss I, Saito T, Johnson JT, et al: Clinical significance of decreased alpha chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res 5: 329-334, 1999
13. Gabrilovich DI, Nadaf S, Corak J, et al: Dendritic cells in antitumor immune responses, II: Dendritic cells grown from bone marrow precursors but not mature DC from tumor bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol 170: 111-119, 1996
14. Tatsumi T, Kierstead LS, Ranieri E, et al: Disease-associated bias in T-helper type 1 (Th1)/Th2 CD4- T-cell responses against MAGE-6 in HLA-DRB10401- patients with renal cell carcinoma or melanoma. J Exp Med 196: 619-628, 2002
15. Berd D, Sato T, Maguire HC Jr, et al: Immunopharmacological analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 22: 403-415, 2004
16. Balch CM, Buzaid AC, Soong S-J, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635-3648, 2001
17. Bittner M, Meltzer P, Chen Y, et al: Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406: 536-540, 2000
18. Weeraratna AT, Jiang Y, Hostetter G, et al: Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1: 279-288, 2002
19. Sondak VK, Liu P-Y, Tuthill RJ, et al: Adjuvant immunotherapy of resected, intermediate-thickness node-negative melanoma with an allogeneic tumor vaccine, I: Overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 20: 2058-2066, 2002
20. Sosman JA, Unger JM, Liu P-Y, et al: Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine, II: Impact of HLA class I antigen expression on outcome. J Clin Oncol 20: 2067-2075, 2002
21. Sosman JA, Unger JM, Liu PY, et al: HLA-A2 and/or HLA-C3 expression defines a subset of T3N0 melanoma patients with improved overall survival from melacine vaccine: An updated analysis of SWOG 9035. Proc Am Soc Clin Oncol 20: 340a, 2002 (abstr 1359)
22. Haigh PI, DiFronzo LA, Gammon G, et al: Vaccine therapy for patients with melanoma. Oncology 13: 1561-1574, 2000
23. Hsueh EC, Essner R, Foshag LJ, et al: Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 20: 4549-4554, 2002